Shire will cut UK R&D to focus on rare diseases


Shire Pharmaceutcals has begun an employee consultation process as it seeks to discontinue a significant proportion of research and development activities at its historic UK base in Basingstoke. The move is part of an ongoing restructuring plan that will see the company focus on treatments for rare diseases.

The Basingstoke site employs around 170 researchers, but many of the research programmes they are engaged in fall outside of Shire’s new target areas, and will be halted. The company has not yet confirmed how many will lose their jobs. The site will continue to provide corporate and support functions in the UK.

Meanwhile, Shire has agreed to pay $4.2 billion (£2.6 billion) for rare disease specialists ViroPharma. The deal brings Shire a clutch of drugs, including Cinryze (C1 esterase inhibitor [human]) for prophylactic treatment of hereditary angioedema (HAE). Shire’s own HAE drug, Firazyr (icatibant), can be used to treat acute attacks of the disease, so the two treatments are complementary.

The deal also includes treatments for adrenal insufficiency and seizures in children and infants, as well as several candidates in Phase II clinical trials.


Related Content

Shire fends off AbbVie takeover bid

23 June 2014 Business

news image

Board says deal undervalues the company and its growth potential

Orphans come in from the cold

30 August 2011 Premium contentFeature

news image

Rare diseases are less rare than you might think, reports Bea Perks, and finding drugs for them can mean big business

Most Read

Linguistic statistics enable synthetic prophetics

17 July 2014 Research

news image

A metric more commonly used by search engines to analyse language can now power organic chemistry retrosyntheses

Coffee cup confusion

20 July 2014 Research

news image

Scientists call for better labelling after research highlights inconsistencies in the chemical composition of a cup of coffee

Most Commented

Royal Society of Chemistry's flagship journal now free to access

16 July 2014 News and Analysis

news image

Chemical Science will follow gold open access model from January 2015 and waive author fees for two years

Science minister replaced in UK cabinet reshuffle

15 July 2014 News and Analysis

news image

Greg Clark replaces David Willetts as minister for science and universities